Literature DB >> 10539881

mRNA expression of variant Fas molecules in acute leukemia cells.

H Inaba1, Y Komada, Q S Li, X L Zhang, S Tanaka, E Azuma, H Yamamoto, M Sakurai.   

Abstract

Fas (Apo-1/CD95) is a cell membrane receptor involved in apoptotic cell death. Soluble variant forms (sFas) lacking the transmembrane domain due to alternative splicing have been identified. Up-regulation of sFas expression is reportedly implicated in prereceptorial blockage of Fas-induced apoptosis in a dose-dependent manner. We examined mRNA expression of Fas and sFas in fresh leukemia cells. All leukemia cells expressed both mRNAs of full-length Fas (FasFull) and sFas with deletion of exon6 (FasDel6). The ratio of FasFull/FasDel6 mRNA expression was not always correlated with Fas-mediated growth inhibition. Interestingly, in a 6-year-old boy with acute myelogenous leukemia, blast cells obtained at onset and at the time of bone marrow relapses expressed distinct amounts of FasDel6 mRNA. Furthermore, the level of FasDel6 expression appeared to be correlated with Fas-resistance in leukemia blasts. In addition, sFas protein levels were elevated in patients' sera at onset with subsequent return to normal levels after complete remission. These results indicated that sFas could be synthesized and released by leukemia blasts and suggested that up-regulation of Fas variant transcript might render leukemia blasts resistant to Fas-mediated growth inhibition in certain cases. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10539881     DOI: 10.1002/(sici)1096-8652(199911)62:3<150::aid-ajh4>3.0.co;2-y

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  The adenovirus E3 RID complex protects some cultured human T and B lymphocytes from Fas-induced apoptosis.

Authors:  Adrienne L McNees; C T Garnett; Linda R Gooding
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 2.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

3.  Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death.

Authors:  Koji Yamanegi; Junko Yamane; Masaki Hata; Hideki Ohyama; Naoko Yamada; Nahoko Kato-Kogoe; Hiroyuki Futani; Keiji Nakasho; Haruki Okamura; Nobuyuki Terada
Journal:  J Cancer Res Clin Oncol       Date:  2008-12-09       Impact factor: 4.553

Review 4.  Aberrant splicing and drug resistance in AML.

Authors:  Rosalia de Necochea-Campion; Geoffrey P Shouse; Qi Zhou; Saied Mirshahidi; Chien-Shing Chen
Journal:  J Hematol Oncol       Date:  2016-09-10       Impact factor: 17.388

5.  Long noncoding RNA Saf and splicing factor 45 increase soluble Fas and resistance to apoptosis.

Authors:  Olga Villamizar; Christopher B Chambers; Janice M Riberdy; Derek A Persons; Andrew Wilber
Journal:  Oncotarget       Date:  2016-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.